AcelRx puts Zalviso NDA resubmission on hold; shares slammed
This article was originally published in Scrip
Shares of AcelRx Pharmaceuticals plummeted about 30% on 5 May after the FDA reiterated its earlier demand that a new clinical trial was needed before the company resubmits its new drug application (NDA) for Zalviso, a pre-programmed, non-invasive, handheld system that delivers 15mcg per dose as needed of the opioid sufentanil, allowing hospital patients to self-dose in managing their pain.
You may also be interested in...
AcelRx reports fast-acting, pain-reducing data for ARX-04 in emergency room-treated trauma patients, which is the setting that most closely resembles battlefield situations experienced by personnel in the US military – the Phase III program's co-funder.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.